0,1,2,3,4
Table 6.5.1:  Randomised phase III controlled trials – nmCRPC,,,,
Study,Intervention,Comparison,Selection criteria,Main outcomes
"ARAMIS
2019, 2020
[1176, 1177]",ADT + darolutamide,ADT + placebo,"nmCRPC; 
baseline 
PSA > 2 ng/mL
PSA-DT < 10 mo.","59% reduction of distant 
progression or death 
Median MFS: darolutamide 
40.4 vs placebo 18.4 mo;
31% reduction in risk of death
HR = 0.69 (95% CI: 0.53–0.88)
p = 0.003"
"PROSPER 
2018, 2020
[1174, 1178]",ADT + enzalutamide,ADT + placebo,"nmCRPC; 
baseline  
PSA > 2 ng/mL
PSA-DT < 10 mo.","71% reduction of distant 
progression or death 
Median MFS: enzalutamide 
36.6 vs placebo 14.7 months;
27% reduction in risk of death
HR = 0.73 (95% CI: 0.61–0.89)
p = 0.001"
"SPARTAN 
2018, 2021
[1175, 1179]",ADT + apalutamide,ADT + placebo,"nmCRPC; 
baseline  
PSA > 2 ng/mL
PSA-DT < 10 mo.","72% reduction of distant 
progression or death
Median MFS: apalutamide  
40.5 vs placebo 16.2 months;
22% reduction in risk of death
HR = 0.78 (95% CI: 0.64–0.96)
p = 0.0161"
